Pipeline Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine BioPharma DiveThe startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.PipelineGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioPharma Dive The startup is developing modified DNA therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. PipelineGene Therapy PlatformRead full story Post navigation Previous: FDA kicks off review of Roche’s Gazyva for wider lupus useNext: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground Related Stories Pipeline Amgen positions MariTide as potential ‘best monthly’ obesity drug pharminent May 1, 2026 Pipeline Merck still sees ‘compelling’ outlook for Terns leukemia drug pharminent April 30, 2026 Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
